Evidence map›Paper›PMID 40782845›Full record

ArticleJournal of substance use and addiction treatment2025

Why is substance use missing from my patient's problem list? CTN research to advance screening, prevention, and treatment of substance use in primary care.

Jennifer McNeely, Katharine A Bradley, Jane M Liebschutz, Geetha A Subramaniam

Abstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jennifer McNeelyNew York University Grossman School of Medicine, Dept. of Population Health, Section on Tobacco, Alcohol, and Drug Use, and Dept. of Medicine, Division of General Internal Medicine and Clinical Innovation; NIDA Clinical Trials Network New York Node, 180 Madison Ave., New York, NY 10016, United States of America. Electronic address: jennifer.mcneely@nyulangone.org.
Katharine A BradleyKaiser Permanente Washington Health Research Institute; University of Washington School of Medicine, Department of Medicine and Health Systems and Population Health; NIDA Clinical Trials Network Health Systems Node, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, United States of America. Electronic address: Katharine.a.bradley@kp.org.
Jane M LiebschutzUniversity of Pittsburgh, UPMC, Center for Research on Health Care, Division of General Internal Medicine; NIDA Clinical Trials Network Appalachian Node, Pittsburgh, PA 15213, United States of America. Electronic address: liebschutzjm@upmc.edu.
Geetha A SubramaniamCenter for Clinical Trials Network, National Institute on Drug Abuse, North Bethesda, MD 20852, United States of America. Electronic address: geetha.subramaniam@nih.org.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Project-008UG1DA049436 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jane M. Liebschutz, Erin L Winstanley · 2019 to 2026
$10.5M
NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA040314NIDA NIH HHS UG1 DA049436
6 · The paper itself

Abstract

While approximately one in five Americans with substance use disorder (SUD) receives treatment in addiction treatment programs, a majority have seen a primary care medical provider in the past year. Recognizing the critical role of primary care in addressing prevention and treatment of unhealthy substance use, for over a decade the National Drug Abuse Treatment Clinical Trials Network (CTN) has supported research to build the tools and evidence needed to support the integration of SUD care, while remaining realistic about the barriers to doing so. Authored by primary care and addiction medicine physician researchers, this commentary provides an overview of CTN primary care-focused research, from developing and implementing substance use screening tools to advancing evidence-based SUD treatment delivery in primary care settings. We identify three priority areas for research and practice innovations: 1) identifying effective treatment interventions to address polysubstance use; 2) improving screening and treatment for cannabis use; and 3) building the evidence base for substance use interventions among non-treatment seeking patients who have unhealthy drug use identified through screening. Addressing these areas can help primary care fulfill its potential as a key component of the substance use services continuum of care.

Indexed as

Addiction treatmentAlcoholDrug usePrimary careScreeningSubstance use disorders

Identifiers

PMID40782845
PMCPMC12427610

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.